English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/133843
COMPARTIR / IMPACTO:
Estadísticas
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Título

α-Galactosidase-A Loaded-Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration

AutorCabrera, Ingrid ; Elizondo, Elisa ; Rivera Gil, Pilar; Moreno, Evelyn; Faraudo, Jordi ; Sala Vergés, Santiago ; Bueno, María Dolores ; González-Mira, Elisabet; Ventosa, Nora ; Veciana, Jaume
Palabras claveRGD targeting
Nanoliposomes
Fabry disease
α-galactosidase A
Compressed CO2
Fecha de publicación6-abr-2016
EditorWorld Scientific Publishing
CitaciónAdvanced Healthcare Materials 5(7): 829- 840 (2016)
ResumenLysosomal storage disorders (LSD) are caused by lysosomal dysfunction usually as a consequence of deficiency of a single enzyme required for the metabolism of macromolecules, such as lipids, glycoproteins, and mucopolysaccharides. For instance, the lack of α-galactosidase A (GLA) activity in Fabry disease patients causes the accumulation of glycosphingolipids in the vasculature leading to multiple organ pathology. Enzyme replacement therapy, which is the most common treatment of LSD, exhibits several drawbacks mainly related to the instability and low efficacy of the exogenously administered therapeutic enzyme. In this work, the unprecedented increased enzymatic activity and intracellular penetration achieved by the association of a human recombinant GLA to nanoliposomes functionalized with Arginine-Glycine-Aspartic acid (RGD) peptides is reported. Moreover, these new GLA loaded nanoliposomes lead to a higher efficacy in the reduction of the GLA substrate named globotriasylceramide in a cellular model of Fabry disease, than that achieved by the same concentration of the free enzyme. The preparation of these new liposomal formulations by DELOS-SUSP, based on the depressurization of a CO-expanded liquid organic solution, shows the great potential of this CO-based methodology for the one-step production of protein-nanoliposome conjugates as bioactive nanomaterials with therapeutic interest. α-galactosidase-A-(GLA)-loaded nano-liposomes functionalized with Arginine-Glycine-Aspartic acid (RGD) peptides are successfully prepared by using compressed CO. This nanoformulation shows an unprecedented increase of the GLA enzymatic activity and intracellular penetration, in comparison to the free enzyme. Moreover, these nanoconjugates lead to a higher efficacy in the reduction of the GLA substrate named globotriasylceramide (Gb3), in a cellular model of Fabry disease, than that achieved by the free enzyme.
URIhttp://hdl.handle.net/10261/133843
DOI10.1002/adhm.201500746
Identificadoresdoi: http://dx.doi.org/10.1002/adhm.201500746
issn: 2192-2659
Aparece en las colecciones: (ICMAB) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
Cabrera_AdvancHealthcMat_2016_postprint.pdf958,05 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo
 

Artículos relacionados:


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.